BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 8550853)

  • 1. Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate.
    Masson E; Relling MV; Synold TW; Liu Q; Schuetz JD; Sandlund JT; Pui CH; Evans WE
    J Clin Invest; 1996 Jan; 97(1):73-80. PubMed ID: 8550853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia.
    Synold TW; Relling MV; Boyett JM; Rivera GK; Sandlund JT; Mahmoud H; Crist WM; Pui CH; Evans WE
    J Clin Invest; 1994 Nov; 94(5):1996-2001. PubMed ID: 7525652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A mathematical model of in vivo methotrexate accumulation in acute lymphoblastic leukemia.
    Panetta JC; Yanishevski Y; Pui CH; Sandlund JT; Rubnitz J; Rivera GK; Ribeiro R; Evans WE; Relling MV
    Cancer Chemother Pharmacol; 2002 Nov; 50(5):419-28. PubMed ID: 12439601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Shortening infusion time for high-dose methotrexate alters antileukemic effects: a randomized prospective clinical trial.
    Mikkelsen TS; Sparreboom A; Cheng C; Zhou Y; Boyett JM; Raimondi SC; Panetta JC; Bowman WP; Sandlund JT; Pui CH; Relling MV; Evans WE
    J Clin Oncol; 2011 May; 29(13):1771-8. PubMed ID: 21444869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo.
    Dervieux T; Brenner TL; Hon YY; Zhou Y; Hancock ML; Sandlund JT; Rivera GK; Ribeiro RC; Boyett JM; Pui CH; Relling MV; Evans WE
    Blood; 2002 Aug; 100(4):1240-7. PubMed ID: 12149204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenomics of intracellular methotrexate polyglutamates in patients' leukemia cells in vivo.
    Lopez-Lopez E; Autry RJ; Smith C; Yang W; Paugh SW; Panetta JC; Crews KR; Bonten EJ; Smart B; Pei D; McCorkle JR; Diouf B; Roberts KG; Shi L; Pounds S; Cheng C; Mullighan CG; Pui CH; Relling MV; Evans WE
    J Clin Invest; 2020 Dec; 130(12):6600-6615. PubMed ID: 33164984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methotrexate polyglutamate levels and co-distributions in childhood acute lymphoblastic leukemia maintenance therapy.
    Nersting J; Nielsen SN; Grell K; Paerregaard M; Abrahamsson J; Lund B; Jonsson OG; Pruunsild K; Vaitkeviciene G; Kanerva J; Schmiegelow K;
    Cancer Chemother Pharmacol; 2019 Jan; 83(1):53-60. PubMed ID: 30324220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of high-dose methotrexate on intracellular 6-mercaptopurine disposition during interval therapy of childhood acute lymphoblastic leukemia.
    Adam de Beaumais T; Dervieux T; Fakhoury M; Medard Y; Azougagh S; Zhang D; Yakouben K; Jacqz-Aigrain E
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):653-8. PubMed ID: 20033410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of methotrexate polyglutamates on thioguanine nucleotide concentrations during continuation therapy of acute lymphoblastic leukemia with mercaptopurine.
    Dervieux T; Hancock M; Evans W; Pui CH; Relling MV
    Leukemia; 2002 Feb; 16(2):209-12. PubMed ID: 11840287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts and treatment outcome in children with B-progenitor-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study.
    Whitehead VM; Shuster JJ; Vuchich MJ; Mahoney DH; Lauer SJ; Payment C; Koch PA; Cooley LD; Look AT; Pullen DJ; Camitta B
    Leukemia; 2005 Apr; 19(4):533-6. PubMed ID: 15716987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time course of methotrexate polyglutamate formation and degradation in the pre-B-leukaemia cell line Nalm6 and in lymphoblasts from children with leukaemia.
    Buchholz B; Frei E; Eisenbarth J; Weigand M; Ludwig R
    Eur J Cancer; 1996 Nov; 32A(12):2101-7. PubMed ID: 9014752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative analysis of methotrexate polyglutamates in lymphoblast preparations from bone marrow and blood, and the contribution of residual red blood cells.
    Weigand M; Frei E; Graf N; Wiessler M
    J Cancer Res Clin Oncol; 2000 Jul; 126(7):407-11. PubMed ID: 10929763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modeling mechanisms of in vivo variability in methotrexate accumulation and folate pathway inhibition in acute lymphoblastic leukemia cells.
    Panetta JC; Sparreboom A; Pui CH; Relling MV; Evans WE
    PLoS Comput Biol; 2010 Dec; 6(12):e1001019. PubMed ID: 21152005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in folylpolyglutamate synthetase and dihydrofolate reductase expression in human B-lineage versus T-lineage leukemic lymphoblasts: mechanisms for lineage differences in methotrexate polyglutamylation and cytotoxicity.
    Galpin AJ; Schuetz JD; Masson E; Yanishevski Y; Synold TW; Barredo JC; Pui CH; Relling MV; Evans WE
    Mol Pharmacol; 1997 Jul; 52(1):155-63. PubMed ID: 9224825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced folate carrier expression in acute lymphoblastic leukemia: a mechanism for ploidy but not lineage differences in methotrexate accumulation.
    Belkov VM; Krynetski EY; Schuetz JD; Yanishevski Y; Masson E; Mathew S; Raimondi S; Pui CH; Relling MV; Evans WE
    Blood; 1999 Mar; 93(5):1643-50. PubMed ID: 10029593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accumulation of high levels of methotrexate polyglutamates in lymphoblasts from children with hyperdiploid (greater than 50 chromosomes) B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group study.
    Whitehead VM; Vuchich MJ; Lauer SJ; Mahoney D; Carroll AJ; Shuster JJ; Esseltine DW; Payment C; Look AT; Akabutu J
    Blood; 1992 Sep; 80(5):1316-23. PubMed ID: 1381244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allopurinol inhibits de novo purine synthesis in lymphoblasts of children with acute lymphoblastic leukemia.
    Masson E; Synold TW; Relling MV; Schuetz JD; Sandlund JT; Pui CH; Evans WE
    Leukemia; 1996 Jan; 10(1):56-60. PubMed ID: 8558939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methotrexate intracellular disposition in acute lymphoblastic leukemia: a mathematical model of gamma-glutamyl hydrolase activity.
    Panetta JC; Wall A; Pui CH; Relling MV; Evans WE
    Clin Cancer Res; 2002 Jul; 8(7):2423-9. PubMed ID: 12114448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia.
    Csordas K; Hegyi M; Eipel OT; Muller J; Erdelyi DJ; Kovacs GT
    Anticancer Drugs; 2013 Feb; 24(2):189-97. PubMed ID: 23187460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics.
    Kager L; Cheok M; Yang W; Zaza G; Cheng Q; Panetta JC; Pui CH; Downing JR; Relling MV; Evans WE
    J Clin Invest; 2005 Jan; 115(1):110-7. PubMed ID: 15630450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.